Market closedNon-fractional
Personalis/PSNL
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Personalis
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.
Ticker
PSNL
Sector
Healthcare
Trading on
NASDAQ
Industry
Life Sciences Tools and Services
Headquarters
Fremont, United States
Employees
224
Website
www.personalis.com
Personalis Metrics
BasicAdvanced
$62M
Market cap
-
P/E ratio
-$1.89
EPS
1.91
Beta
-
Dividend rate
Price and volume
Market cap
$62M
Beta
1.91
Financial strength
Current ratio
3.839
Quick ratio
3.403
Long term debt to equity
31.782
Total debt to equity
39.623
Interest coverage (TTM)
-1,239.36%
Management effectiveness
Return on assets (TTM)
-23.86%
Return on equity (TTM)
-58.92%
Valuation
Price to revenue (TTM)
0.789
Price to book
0.51
Price to tangible book (TTM)
0.51
Price to free cash flow (TTM)
-0.858
Growth
Revenue change (TTM)
7.96%
Earnings per share change (TTM)
-23.22%
3-year revenue growth
-2.65%
3-year earnings per share growth
16.39%
What the Analysts think about Personalis
Analyst Ratings
Majority rating from 6 analysts.
Personalis Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$20M
-0.51%
Net income
-$13M
-51.32%
Profit margin
-66.15%
-51.07%
Personalis Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.50
-$0.60
-$0.54
-$0.26
-
Expected
-$0.53
-$0.53
-$0.50
-$0.41
-$0.37
Surprise
-5.87%
14.03%
8.00%
-36.07%
-
Personalis News
AllArticlesVideos
Personalis to Participate at the TD Cowen 3rd Annual Tools / Dx Revolution Conference
Business Wire·3 weeks ago
Personalis Provides Dial-in and Updated Date for ASCO Highlights Conference Call
Business Wire·3 weeks ago
Personalis Announces Start of Cancer MRD Testing Commercialization Collaboration with Tempus
Business Wire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Personalis stock?
Personalis (PSNL) has a market cap of $62M as of July 06, 2024.
What is the P/E ratio for Personalis stock?
The price to earnings (P/E) ratio for Personalis (PSNL) stock is 0 as of July 06, 2024.
Does Personalis stock pay dividends?
No, Personalis (PSNL) stock does not pay dividends to its shareholders as of July 06, 2024.
When is the next Personalis dividend payment date?
Personalis (PSNL) stock does not pay dividends to its shareholders.
What is the beta indicator for Personalis?
Personalis (PSNL) has a beta rating of 1.91. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Personalis stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.